U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT06952075) titled 'GR1803 Injection in Patients With RRMM' on April 23.
Brief Summary: All subjects will receive GR1803 injection until intolerable toxicity or investigator-assessed disease progression occurs (except in cases of disease progression due to discontinuation of the drug as a result of an adverse event) or until the subject has been administered the drug for 2 years or until the subject withdraws consent or until the investigator determines that the subject needs to be discontinued.
Study Start Date: April 24
Study Type: INTERVENTIONAL
Condition:
Multiple Myleoma
Intervention:
DRUG: GR1803
D1 given at a dose of 10ug/kg, D4 given at a ...